|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500106834 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-30 17:40:47 |
|
注册时间: Date of Registration: |
2025-07-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
艾玛昔替尼治疗中重度活动性类风湿关节炎有效性及安全性的前瞻性、多中心研究(IMPROVE-RA) |
|
Public title: |
A Prospective, Multicenter Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis(IMPROVE-RA) |
|
注册题目简写: |
IMPROVE-RA |
|
English Acronym: |
IMPROVE-RA |
|
研究课题的正式科学名称: |
艾玛昔替尼治疗中重度活动性类风湿关节炎有效性及安全性的前瞻性、多中心研究(IMPROVE-RA) |
|
Scientific title: |
A Prospective, Multicenter Study on the Efficacy and Safety of Ivarmacitinib in the Treatment of Moderate-to-Severe Active Rheumatoid Arthritis(IMPROVE-RA) |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陆坦 |
研究负责人: |
孙凌云 |
|
Applicant: |
Lu Tan |
Study leader: |
Sun Lingyun |
|
申请注册联系人电话: Applicant telephone: |
+86 198 4456 5565 |
研究负责人电话:
Study leader's |
+86 137 0518 6409 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
415958830@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
lingyunsun2012@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区金峰大厦 |
研究负责人通讯地址: |
江苏省南京市中山路321号 |
|
Applicant address: |
Jiangsu Province, Nanjing City, Gulou District, Jinfeng Building |
Study leader's address: |
No. 321 Zhongshan Road, Nanjing, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
江苏恒瑞医药股份有限公司 |
||
|
Applicant's institution: |
Hengrui Pharmaceuticals Co., Ltd. |
||
|
研究负责人所在单位: |
南京大学医学院附属鼓楼医院 |
||
|
Affiliation of the Leader: |
Nanjing DrumTower Hospital of Nanjing University Medical School |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025-0468-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京大学医学院附属鼓楼医院医学伦理委员会 |
||
|
Name of the ethic committee: |
IRB of Nanjing DrumTower Hospital of Nanjing University Medical School |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-07-07 00:00:00 | ||
|
伦理委员会联系人: |
戴红阳 |
||
|
Contact Name of the ethic committee: |
Ding Congzhu |
||
|
伦理委员会联系地址: |
江苏省南京市中山路321号 |
||
|
Contact Address of the ethic committee: |
No. 321 Zhongshan Road, Nanjing, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 135 8404 6547 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
南京大学医学院附属鼓楼医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing DrumTower Hospital of Nanjing University Medical School |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市中山路321号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 321 Zhongshan Road, Nanjing, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
江苏恒瑞医药股份有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hengrui Pharmaceuticals Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
类风湿关节炎 |
||||||||||||||||||||||
|
Target disease: |
Rheumatoid Arthritis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价艾玛昔替尼片治疗中国中重度活动性类风湿关节炎(RA)患者中的疗效和安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the efficacy and safety of Ivarmacitinib Tablets in Chinese patients with moderate-to-severe active rheumatoid arthritis |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 自愿在与本研究相关的活动开始前签署知情同意书,并能够理解本研究的程序和方法,愿意严格遵守临床研究方案完成本研究; 2. 签署知情同意书时的年龄18~75周岁(包括两端值),性别不限; 3. 符合美国风湿病学会(ACR)1987年推出的RA诊断标准或美国风湿病学会(ACR)和欧洲抗风湿联盟(EULAR)2010年联合推出RA诊断标准,诊断为类风湿关节炎的患者;筛选时ACR功能分类I-III级。 4. 患有中至重度活动性RA,定义为筛选时基于68/66个关节计数,压痛关节计数(TJC)≥6个或肿胀关节计数(SJC)≥6个,且筛选时红细胞沉降率(ESR)>28 mm/h或C反应蛋白(CRP)/超敏CRP(hsCRP)>5 mg/L。 5. 有生育能力的女性受试者必须在首次给药前7天内进行血清妊娠试验且检查结果为阴性,且不在哺乳期,必须同意在试验期间和末次给予艾玛昔替尼片后1个月内采用有效避孕措施;对于伴侣为有生育能力的妇女的男性受试者,须同意从签署知情同意书开始直到末次给艾玛昔替尼片后1个月内采用可靠方法避孕。在同一时间段内男性受试者也必须同意不捐精子。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Voluntarily sign the Informed Consent Form prior to any study-related procedures, demonstrate understanding of the study procedures and methods, and commit to strict adherence to the clinical protocol; 2. Aged 18–75 years (inclusive) at the time of signing informed consent, regardless of gender; 3. Meet the 1987 ACR RA diagnostic criteria or the 2010 ACR/EULAR RA classification criteria, with an ACR functional class I–III at screening; 4. Moderate-to-severe active RA at screening, defined as:Tender Joint Count (TJC) >=6 or Swollen Joint Count (SJC) >=6 (based on 68/66 joints), and Erythrocyte Sedimentation Rate (ESR) >28 mm/h or C-reactive Protein (CRP)/high-sensitivity CRP (hsCRP) >5 mg/L; 5. Female subjects of childbearing potential must:Have a negative serum pregnancy test within 7 days prior to the first dose,Be non-lactating, Agree to use effective contraception during the trial and for 1 month after the last dose of Emasitinib Tablets;Male subjects with partners of childbearing potential must agree to use reliable contraception from signing informed consent until 1 month after the last dose, and refrain from sperm donation during this period. |
||||||||||||||||||||||
|
排除标准: |
1. 既往接受过规范疗程JAK抑制剂(例如:托法替布、乌帕替尼、巴瑞替尼、非戈替尼、氘可来昔替尼等,包括外用制剂)治疗原发性失效的受试者; 2. 研究者判断为目前处于症状活跃的原发性纤维肌痛等影响RA症状判定疾病的患者; 3. 哺乳期或妊娠期妇女受试者,或在整个试验期间及末次给予艾玛昔替尼片后1个月内不愿意采取有效避孕措施的具有生育能力的受试者; 4. 无法控制的感染患者,如乙肝携带者伴肝功能障碍(谷草转氨酶或谷丙转氨酶≥实验室正常值上限的3倍,或胆红素≥实验室正常值上限的1.5倍)的患者;有潜伏性或活动性结核病病史且未进行足够抗结核治疗疗程的患者等; 5. 经简化肾脏病饮食调整(MDRD)公式计算或其他方法估算的肾小球滤过率(eGFR)<60 mL/min/1.73 m2; 6. 有中度至重度充血性心力衰竭(纽约心脏病协会III或IV级),入组前6个月内发生过导致住院的心脑血管事件,包括但不限于经皮冠状动脉腔内血管成形术、冠状动脉搭桥术、脑出血、蛛网膜下腔出血; 7. 患有恶性肿瘤或有恶性肿瘤病史(除经充分治疗或切除的皮肤非转移性基底细胞癌或鳞状细胞癌,或者宫颈原位癌)的患者; 8. 筛选期前30天内参加过其他临床试验的患者; 9. 拒绝签署知情同意书者,不愿意或不能配合采集病史及临床图片的患者; 10. 研究者认为有其他任何不适宜参与本次研究情况的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Prior primary failure to JAK inhibitors (e.g., tofacitinib, upadacitinib, baricitinib, filgotinib, deucravacitinib, including topical agents) after standard treatment courses; 2. Presence of active primary fibromyalgia or other conditions affecting RA symptom assessment, as confirmed by the investigator; 3. Lactating or pregnant women, or subjects of childbearing potential unwilling to use effective contraception during the trial and for 1 month post-last-dose; 4. Uncontrolled infections, e.g.:HBV carriers with hepatic dysfunction (AST/ALT >=3×ULN or bilirubin >=1.5×ULN),History of latent/active tuberculosis without sufficient anti-TB therapy; 5. eGFR <60 mL/min/1.73 m2 (calculated by MDRD or other validated methods); 6. Moderate-to-severe congestive heart failure (NYHA class III/IV) or cardiovascular events requiring hospitalization within 6 months (e.g., PTCA, CABG, cerebral/subarachnoid hemorrhage); 7. Malignancy history (except adequately treated non-metastatic basal/squamous cell skin cancer or carcinoma in situ of the cervix); 8. Participation in other clinical trials within 30 days before screening; 9. Refusal to sign informed consent or inability to cooperate with medical history collection; 10. Any other condition deemed unsuitable by the investigator. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-07 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-31 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
none |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
基于受试者隐私,不公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
In order to protect participant privacy, the raw data will remain confidential and not be publicly released. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |